• Home
  • About
    • About Panaxea
    • Meet our team
    • Careers
  • Services
    • Health Technology Assessment
    • Health Services & Systems Research
    • Health Innovation Assessment Consultancy
  • News & Cases
  • Publications
  • Contact
  • Privacy Statement Panaxea

Lotte Steuten worked along with Anna Miquel-Cases, Valesca Retèl, and Wim van Harten on a paper on decision about design and priority of studies of emerging predictive biomarkers of high-dose alkylating chemotherapy (HDAC) in triple-negative breast cancer (TNBC). The paper was published in Value in Health.

The information was gathered by a value-of-information analysis. The study shows that further research should be prioritized to the parameter group including “biomarkers’ prevalence, positive predictive value (PPV), and treatment response rates (TRRs).

The full paper can be found here.

Panaxea b.v. supports decision making in healthcare by assessing the relative advantage of healthcare innovations. Our clients include patients, health and life science innovators and investors, health technology adopters, public and private payers, and policymakers.

Follow us on Twitter

Tweets by @PANAXEA

Useful Links

Home
About Panaxea
Services
Publications
Contact Us

Social Media

 Twitter Linkedin

Contact Information

PANAXEA b.v.
Matrix II, unit 1.10
Science Park 400
1098 XH Amsterdam
The Netherlands

+31 20 7400 778
www.panaxea.eu
info@panaxea.eu

© 2019 Panaxea. All Rights Reserved.
  • Privacy Statement Panaxea
  • No translations available for this page